Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project.

ESMO open·2024
Same author

Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2024
Same author

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.

ESMO open·2023
Same author

Heart failure in patients is associated with downregulation of mitochondrial quality control genes.

European journal of clinical investigation·2023
Same author

siMS score- method for quantification of metabolic syndrome, confirms co-founding factors of metabolic syndrome.

Frontiers in genetics·2023
Same author

Theory of the Supercurrent Diode Effect in Rashba Superconductors with Arbitrary Disorder.

Physical review letters·2022

Related Experiment Video

Updated: May 25, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.

P Sikiric1, S Seiwerth, R Rucman

  • 1Department of Pharmacology, Medical Faculty University of Zagreb, Salata 11, POB 916, 10000 Zagreb, Croatia. sikiric@mef.hr

Current Medicinal Chemistry
|February 4, 2012
PubMed
Summary

Stable gastric pentadecapeptide BPC 157 demonstrates significant potential for treating inflammatory bowel disease (IBD) and promoting wound healing. Its safety profile and efficacy in gastrointestinal tract conditions suggest a promising therapeutic agent.

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Related Experiment Videos

Last Updated: May 25, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Area of Science:

  • Gastroenterology and Pharmacology
  • Peptide Therapeutics
  • Inflammatory Bowel Disease Research

Background:

  • Stable gastric pentadecapeptide BPC 157 is a novel therapeutic agent with demonstrated efficacy in the gastrointestinal tract.
  • BPC 157 exhibits an antiulcer effect and is effective in inflammatory bowel disease (IBD) therapy.
  • The peptide has a favorable safety profile, with no observed toxic effects in trials.

Purpose of the Study:

  • To evaluate the therapeutic potential of BPC 157 in inflammatory bowel disease (IBD) and gastrointestinal wound healing.
  • To investigate the mechanism of action of BPC 157, including its interaction with the NO-system and its angiogenic effects.
  • To assess the safety and tolerability of BPC 157 for long-term use in IBD therapy.

Main Methods:

  • Review of preclinical animal studies and clinical phase II trials of BPC 157 (PL 14736).
  • Analysis of BPC 157's effects on gastrointestinal healing, including intestinal anastomosis, short bowel syndrome, and fistula healing.
  • Examination of BPC 157's interaction with the NO-system and its impact on gene expression related to inflammation and healing.

Main Results:

  • BPC 157 demonstrated significant wound healing effects and potential in treating IBD.
  • The peptide stimulates the expression of genes involved in cytokine and growth factor generation, promoting extracellular matrix formation.
  • Studies indicated endothelium protection and angiogenic effects, even in compromised conditions.

Conclusions:

  • BPC 157 shows high significance for future IBD therapy, supported by animal studies on advanced intestinal healing.
  • Its safety profile and lack of toxicity make it a viable alternative to other peptidergic agents for long-term treatment.
  • BPC 157 represents a promising therapeutic candidate for managing complex gastrointestinal conditions and promoting healing.